Orsik-E 250 mg Tablet 10's

Orsik-E 250 mg Tablet 10's belongs to the class of antihemorrhagic drugs. It is indicated in the treatment of small vessel haemorrhage menorrhagia (menstrual bleeding that lasts more than 7 days) including IUD users and prophylaxis of periventricular haemorrhage in neonates. It prevents and controls bleeding from small blood vessels and neonatal intraventricular haemorrhage. Besides this, Orsik-E 250 mg Tablet 10's can prevent periventricular haemorrhages in prematurely born children.

Orsik-E 250 mg Tablet 10's contains Etamsylate, a hemostatic agent that improves platelet adhesion by restoring capillary resistance and improving platelet adhesion. On the other hand, this medicine also inhibits the biosynthesis and action of prostaglandin. These effects help to decrease abnormal bleeding.

Orsik-E 250 mg Tablet 10's should be used as prescribed by the physician. Orsik-E 250 mg Tablet 10's may cause side effects such as headache, skin rash, nausea and low blood pressure. These side effects are short and may go away with time; however, if they continue, consult a doctor.

Inform your doctor if you are allergic to any medications and foods, if you have acute porphyria, fever, non-cancerous growths or blood pigment disorder, or if you are pregnant or breastfeeding. Orsik-E 250 mg Tablet 10's is not recommended to use before the onset of bleeding during periods, so inform your doctor about your condition. And also, notify your doctor about your current list of medications, pre-existing diseases, and current health conditions (e.g. pregnancy, upcoming surgery, etc.) in order to rule out any potential negative effects.

Orsik-E 250 mg Tablet 10's contains Etamsylate, a hemostatic agent that improves platelet adhesion by restoring capillary resistance and improving platelet adhesion. On the other hand, Orsik-E 250 mg Tablet 10's also inhibits the biosynthesis and action of the prostaglandin. These effects help to decrease abnormal bleeding. Thus it treats, controls, and improves various disease conditions and symptoms.

• Headache
• Skin Rash
• Nausea
• Low Blood Pressure

Before prescribing the Orsik-E 250 mg Tablet 10's, let your doctor know if you are allergic to any medications and foods if you have acute porphyria, bronchial asthma, fever, non-cancerous growths or blood pigment disorder, or if you are pregnant or breastfeeding a baby. Orsik-E 250 mg Tablet 10's is recommended not to use before the onset of bleeding during periods, so inform your doctor about your condition. And also, inform your doctor about your current list of medications (including vitamins and supplements), pre-existing diseases, and current health conditions (e.g. pregnancy, upcoming surgery, etc.) in order to rule out any potential negative effects.

Drug-Drug interactions: No interactions found or established.

Drug-Food interactions: No interactions found or established.

Drug-Disease interactions: Orsik-E 250 mg Tablet 10's may interact with disease conditions, including bronchial asthma, acute porphyria, fever, non-cancerous growths or blood pigment disorder. So, inform your doctor about your medical condition.

• Maintain a healthy weight. Stay physically active.
• Consume fresh fruits and vegetables. Avoid spicy, salty, and deep-fried foods. Eating healthy can help you to recover faster.
• Avoid tea, coffee, and cold drinks.
• Drink plenty of fluids to stay hydrated. Fluids are necessary to maintain blood flow in your body.
• Avoid the intake of alcoholic beverages as it can make you dehydrated and also can affect your sleep.
• Avoid physical and psychological stress.

Bleeding disorders: Bleeding disorders are a group of diseases that occur when the blood fails to clot properly. Platelets, a type of blood cell, stick together and form a plug at the site of an injured blood vessel during normal clotting. Clotting factors, which are proteins in the blood, then interact to form a fibrin clot, which is essentially a gel plug that holds platelets in place and allows healing to occur at the site of the injury while preventing blood from escaping the blood vessel. While excessive clotting can result in conditions such as heart attacks and strokes, the inability to form clots can be equally dangerous, resulting in excessive bleeding. Bleeding can occur as a result of insufficient or abnormal platelets, insufficient or abnormal clotting proteins, or abnormal blood vessels.

Haemorrhage menorrhagia: Menstrual periods with very excessive or protracted bleeding are known medically as menorrhagia. Despite the fact that most women worry about their periods being heavy, menorrhagia is not a regular occurrence in most women.

Neonatal intraventricular haemorrhage: A newborn’s intraventricular haemorrhage (IVH) is bleeding into the fluid-filled regions, or ventricles, that surround the brain. The condition is more common in preterm babies, and the smaller and more premature the infant, the greater the risk for IVH. This is due to the fact that blood vessels in premature infants' brains have not yet fully matured and are extremely fragile. IVH is rarely present at birth, and if it does occur, it is usually in the first few days of life.

Periventricular-intraventricular haemorrhage is a disorder that primarily affects premature newborn infants born before 33 weeks of gestation. Haemorrhage develops when arteries in the periventricular portion of the germinal matrix break and expand into the intraventricular space. Periventricular haemorrhage occurs when bleeding extends into the intraparenchymal area next to the ventricle.